Clarient to Release 2009 Third Quarter Financial Results on Tuesday, November 3rd

Conference Call and Audio Webcast Scheduled for 5:00 pm EST

ALISO VIEJO, Calif., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Clarient, Inc. (Nasdaq:CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will report its financial results for the third quarter ended September 30, 2009 after the stock market closes on Tuesday, November 3rd.

 Date: Tuesday, November 3, 2009

 Start Time: 5:00 pm EST

 Call-in Number: 1-888-549-7704 (U.S.) / 480-629-9857 (International)

 Conference ID Number: 4177526

 Webcast: www.clarientinc.com/investor

 Web Replay: For those unable to participate in the live broadcast, a
 replay of the webcast will be archived at
 www.clarientinc.com/investor shortly after the call, and will be
 available for one year.

 Speakers: Ron Andrews, Vice Chairman and CEO; Michael Pellini, MD,
 President and COO; Raymond Land, CFO

 Format: Presentation of third quarter 2009 financial results followed
 by Q&A

About Clarient

Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and development into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine has created the need for a centralized resource which provides leading oncology diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory, which provides the most advanced oncology testing and diagnostic services available. Resulting diagnostic reports and analyses are made available to customers through Clarient's Internet-based portal, PATHSiTE. Clarient also plans to develop and market new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. www.clarientinc.com

CONTACT:  Allen & Caron Inc
          Matt Clawson
          949.474.4300 
          matt@allencaron.com